Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Via G. Venezian, Milan, Italy.
Eur J Cancer. 2012 Dec;48(18):3448-55. doi: 10.1016/j.ejca.2012.06.017. Epub 2012 Jul 24.
Previous studies have reported a poor outcome for synovial sarcoma patients whose tumours relapse.
This study analysed 44 relapsing cases in a series of 118 consecutive patients <21 yr of age with non-metastatic synovial sarcoma prospectively enrolled in Italian paediatric protocols between 1979 and 2006. In an effort to identify a possible risk-adapted stratification enabling a better planning of second-line treatment, the relapsing patients' outcome was analysed vis-à-vis their clinical picture at onset, first-line treatments, clinical findings at the time of first relapse and second-line treatment modalities.
The first event was a local recurrence in only 15 cases, and metastatic in 29 (associated with local relapse too in 7 cases). The time to relapse ranged from 4 to 108 months (median 20 months). Overall survival was 29.7% and 21.0% five and ten years after relapsing, respectively. The variables influencing survival were the timing and type of relapse (combined) and the chances of a secondary remission, which correlated strongly with the feasibility of complete surgery.
Our study confirmed a largely unsatisfactory prognosis after recurrences in children and adolescents with synovial sarcoma: the chances of survival can be estimated on the basis of several variables for the purposes of planning risk-adapted salvage protocols. An aggressive surgical approach should be recommended. New effective systemic agents are warranted, and experimental therapies can be offered to patients with little chance of salvage.
先前的研究报告显示,滑膜肉瘤患者肿瘤复发的预后较差。
本研究分析了 1979 年至 2006 年期间,意大利儿科方案前瞻性纳入的 118 例连续非转移性滑膜肉瘤患者中,44 例复发患者的病例。为了确定一种可能的风险分层,以便更好地规划二线治疗,分析了复发患者的临床特征、一线治疗、首次复发时的临床发现和二线治疗方式。
首次事件仅为局部复发 15 例,远处转移 29 例(其中 7 例合并局部复发)。复发时间为 4 至 108 个月(中位数为 20 个月)。复发后 5 年和 10 年的总生存率分别为 29.7%和 21.0%。影响生存的变量是复发的时间和类型(联合)以及继发性缓解的机会,这与完全手术的可行性密切相关。
我们的研究证实了儿童和青少年滑膜肉瘤复发后的预后仍然很差:根据几个变量可以估计生存的机会,以便为制定风险适应的挽救方案提供参考。应推荐积极的手术方法。需要新的有效的系统治疗药物,并且可以为挽救机会较小的患者提供实验性治疗。